Lawyers representing 10 groups of plaintiffs, or 80,000 liability cases across the US, have backed the payout. There remain another few thousand cases not covered by the payout. GSK will also pay a ...

GSK’s ViiV Healthcare unit is countering rival ... tripling the company’s current yearly supply. The move involves the company’s long-acting cabotegravir (CAB LA), a PrEP medication made ...

GSK has pledged to 100% use of renewable across the company by 2025, and an 80% reduction in carbon emissions by 2030 en route to net zero across all its supply chain – including purchased goods ...

CSL Seqirus, Sanofi and GSK have collectively secured $72 million in funding from the U.S. health department to boost the ...

GSK GSK3.22%increase; green up pointing triangle agreed to pay more than $2 billion to settle almost all remaining liability cases in the U.S. over allegations its discontinued heartburn medicine ...

The company, which is majority owned by GSK and counts Pfizer and Shionogi as stockholders, is committing to supply at least 2 million doses of its long-acting drug cabotegravir for pre-exposure ...

GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in ...

The latest award, which includes $37.9 million for CSL, $23.4 million for Sanofi and $10.5 million for GSK, would more than double the nation’s supply of shots targeting bird flu. “That is ...

A new $72 million award aims to double the U.S. supply of bird flu vaccine shots ... As part of the agreement, GSK, Sanofi, and CSL will produce extra bulk vaccine components tailored to the ...

The Energize program is a supply chain renewables initiative designed ... Charles River Laboratories, Chiesi Group, GSK, Haleon, Johnson & Johnson, Kenvue, Merck (known as MSD outside the United ...

iTeos Therapeutics (NASDAQ:ITOS) announced Saturday that its experimental cancer doublet therapy developed with GSK (NYSE:GSK) outperformed the British drugmaker’s FDA-approved anti-PD-1 therapy ...

GlaxoSmithKline Pharma ... conventional portfolios of generics in a bid to ascend higher on the value chain and focus on high-value therapeutics. "We will continue to push on the innovation ...